Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 70,885 Shares of Stock

Protara Therapeutics, Inc. (NASDAQ:TARAGet Free Report) major shareholder Opaleye Management Inc. sold 70,885 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $3.25, for a total value of $230,376.25. Following the sale, the insider now owns 126,050 shares of the company’s stock, valued at $409,662.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

  • On Thursday, May 9th, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics stock. The stock was sold at an average price of $3.09, for a total value of $94,554.00.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA opened at $3.09 on Friday. The business’s 50-day moving average is $3.38 and its 200 day moving average is $2.66. Protara Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $5.24. The firm has a market capitalization of $63.62 million, a P/E ratio of -0.83 and a beta of 1.80.

Protara Therapeutics (NASDAQ:TARAGet Free Report) last announced its earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.13. On average, analysts expect that Protara Therapeutics, Inc. will post -3.56 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on TARA. HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, May 6th. Oppenheimer upped their target price on Protara Therapeutics from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Monday, April 22nd.

Get Our Latest Stock Analysis on Protara Therapeutics

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. acquired a new stake in Protara Therapeutics, Inc. (NASDAQ:TARAFree Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned 0.09% of Protara Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

(Get Free Report)

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

Read More

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with's FREE daily email newsletter.